Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Open Access
- 1 October 1991
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 88 (4) , 1282-1290
- https://doi.org/10.1172/jci115432
Abstract
Increased nonesterified fatty acid (NEFA) levels may be important in causing insulin resistance in skeletal muscles in patients with non-insulin-dependent diabetes mellitus (NIDDM). The acute effect of the antilipolytic nicotinic acid analogue Acipimox (2 X 250 mg) on basal and insulin-stimulated (3 h, 40 mU/m2 per min) glucose metabolism was therefore studied in 12 patients with NIDDM. Whole-body glucose metabolism was assessed using [3-3H]glucose and indirect calorimetry. Biopsies were taken from the vastus lateralis muscle during basal and insulin-stimulated steady-state periods. Acipimox reduced NEFA in the basal state and during insulin stimulation. Lipid oxidation was inhibited by Acipimox in all patients in the basal state (20 +/- 2 vs. 33 +/- 3 mg/m2 per min, P less than 0.01) and during insulin infusion (8 +/- 2 vs. 17 +/- 2 mg/m2 per min, P less than 0.01). Acipimox increased the insulin-stimulated glucose disposal rate (369 +/- 49 vs. 262 +/- 31 mg/m2 per min, P less than 0.01), whereas the glucose disposal rate was unaffected by Acipimox in the basal state. Acipimox increased glucose oxidation in the basal state (76 +/- 4 vs. 50 +/- 4 mg/m2 per min, P less than 0.01). During insulin infusion Acipimox increased both glucose oxidation (121 +/- 7 vs. 95 +/- 4 mg/m2 per min, P less than 0.01) and nonoxidative glucose disposal (248 +/- 47 vs. 167 +/- 29 mg/m2 per min, P less than 0.01). Acipimox enhanced basal and insulin-stimulated muscle fractional glycogen synthase activities (32 +/- 2 vs. 25 +/- 3%, P less than 0.05, and 50 +/- 5 vs. 41 +/- 4%, P less than 0.05). Activities of muscle pyruvate dehydrogenase and phosphofructokinase were unaffected by Acipimox. In conclusion, Acipimox acutely improved insulin action in patients with NIDDM by increasing both glucose oxidation and nonoxidative glucose disposal. This supports the hypothesis that elevated NEFA concentrations may be important for the insulin resistance in NIDDM. The mechanism responsible for the increased insulin-stimulated nonoxidative glucose disposal may be a stimulatory effect of Acipimox on glycogen synthase activity in skeletal muscles.Keywords
This publication has 55 references indexed in Scilit:
- Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1990
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormonesDiabetes/Metabolism Research and Reviews, 1988
- Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism.Journal of Clinical Investigation, 1987
- The mammalian pyruvate dehydrogenase complex: Structure and regulationPublished by Springer Nature ,1983
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975
- Active and inactive forms of pyruvatedehydrogenase in skeletal muscle as related to the metabolic and functional state of the muscle cellFEBS Letters, 1975
- The Influence of Insulin on Glucose and Fatty Acid Metabolism in the Isolated Perfused Rat Hind QuarterHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1975
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972
- THE GLUCOSE FATTY-ACID CYCLE ITS ROLE IN INSULIN SENSITIVITY AND THE METABOLIC DISTURBANCES OF DIABETES MELLITUSPublished by Elsevier ,1963